Biotech News
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
investor.inva.com2026-05-06 20:14 EST
Generated $58.6 million in revenue from resilient royalties portfolio Achieved IST U.S. net product sales of $34.2 million for the first quarter, representing 29% year-over-year growth Significant value created across strategic healthcare asset portfolio BURLINGAME, Calif.